Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 452,189
  • Shares Outstanding, K 84,050
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 36-Month Beta 2.26
  • Price/Sales 1,084.67
  • Price/Cash Flow N/A
  • Price/Book 2.75
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.43
  • Most Recent Earnings -0.04 on 03/15/18
  • Next Earnings Date 05/21/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +7.19%
on 04/03/18
5.65 -4.96%
on 04/19/18
-0.01 (-0.19%)
since 03/26/18
3-Month
4.76 +12.82%
on 02/06/18
5.99 -10.35%
on 03/16/18
-0.25 (-4.45%)
since 01/26/18
52-Week
4.41 +21.77%
on 12/19/17
8.19 -34.43%
on 05/15/17
-1.99 (-27.04%)
since 04/26/17

Most Recent Stories

More News
Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare...

AUP.TO : 6.91 (+0.58%)
AUPH : 5.37 (-0.19%)
Research Reports on Aurinia Pharma, Immunovaccine, IntelliPharmaCeutics International, and OrganiGram Holdings

LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Aurinia Pharmaceuticals, Immunovaccine,...

AUP.TO : 6.91 (+0.58%)
AUPH : 5.37 (-0.19%)
OGRMF : 3.0000 (-2.08%)
IPCI : 0.38 (unch)
New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SINOPEC Shangai Petrochemical...

VRX.TO : 22.91 (+1.55%)
AUPH : 5.37 (-0.19%)
SHI : 66.58 (+0.56%)
KNOP : 20.65 (+0.49%)
VRX : 17.76 (+1.25%)
SMBC : 34.90 (+0.29%)
DCM : 25.60 (-1.35%)
Free Research Reports on These Biotech Stocks -- Omeros, Argos Therapeutics, Array BioPharma, and Aurinia Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on OMER, ARGS, ARRY, and AUPH which can be accessed for free by signing up to www.wallstequities.com/registration....

AUPH : 5.37 (-0.19%)
ARGS : 0.2100 (-27.59%)
ARRY : 13.81 (-0.14%)
OMER : 14.82 (+8.02%)
Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference...

AUP.TO : 6.91 (+0.58%)
AUPH : 5.37 (-0.19%)
Blog Exposure - Aclaris Therapeutics Shares Positive Update on Phase-2 Results after a 3-Month Follow-Up of A-101 45% Topical Solution

Stock Monitor: Aurinia Pharma Post Earnings Reporting

AUPH : 5.37 (-0.19%)
ACRS : 17.79 (+0.34%)
Aurinia Pharmaceuticals, Voclosporin Updates, Analysts Target Price and 2018 Outlook

NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive...

AUPH : 5.37 (-0.19%)
Aurinia Pharmaceuticals Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern...

AUPH : 5.37 (-0.19%)
Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

--Trials in FSGS and Dry Eye to begin in Q2 2018

AUP.TO : 6.91 (+0.58%)
AUPH : 5.37 (-0.19%)
Consolidated Research: 2018 Summary Expectations for B Communications, Student Transportation, Aurinia Pharmaceuticals, Grifols, S.A., NEXEO SOLUTIONS, and ASML Holding N.V. -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of B Communications Ltd. (NASDAQ:BCOM),...

BCOM : 12.11 (-4.04%)
STB : 7.50 (unch)
NXEO : 10.33 (-1.71%)
AUPH : 5.37 (-0.19%)
NXEOU : 11.75 (+10.64%)
GRFS : 20.23 (+0.35%)
ASML : 195.68 (+2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 5.50
1st Resistance Point 5.44
Last Price 5.37
1st Support Level 5.32
2nd Support Level 5.26

See More

52-Week High 8.19
Fibonacci 61.8% 6.75
Fibonacci 50% 6.30
Fibonacci 38.2% 5.85
Last Price 5.37
52-Week Low 4.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar